Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Defining the relationship between clinician-preferred ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer

View through CrossRef
Abstract Background Performance status and health-related quality of life (HRQoL) are important parameters in the management of metastatic prostate cancer. The clinician-preferred Eastern Cooperative Oncology Group performance status (ECOG-PS) may not relate with the patient-described HRQoL because the later puts into consideration some aspects of health that are not captured by the former. The aim of this study is to define the relationship between clinician-preferred ECOG-PS and the patient-determined HRQoL in men with metastatic hormone-naïve prostate cancer (mPCa). Methods An analytical cross-sectional study recruiting patients presenting with mPCa in Enugu, southeast Nigeria. Two clinicians agreed on an ECOG-PS score for each study participant who in turn completed the FACT-P and the EQ-5D-5L questionnaires with interviewer-assistance where necessary. Other medical information was retrieved from the records. ANOVA and chi-square tests were used to compare available data across ECOG-PS preferences and ordinal logistic regression was used to determine the FACT-P questionnaire items that related significantly with the ECOG-PS preferences. Results Of the 224 participants (mean age: 70.62 ± 7.34), about 60.7% had ≥ 12years of formal education and 84.9% had ISUP grade ≥ 3 cancer. In all, 22.8%, 55.8%, 21.0% and 0.4% were ECOG-PS 1, ECOG-PS 2, ECOG-PS 3 and ECOG-PS 4 respectively while the mean FACT-P score, EQ-HVI and EQ-VAS score were 80.18 ± 17.56, 0.524 ± 0.324 and 60.43 ± 9.91% respectively. The FACT-P score (p = 0.002), EQ-HVI (p < 0.001) and EQ-VAS score (p < 0.001) varied significantly across the ECOG-PS categories. Within the FACT-P, only questionnaire items GP3 (p = 0.024) and GP7 (p < 0.001) of the PWB domain, and items GF5 (p = 0.009) and GF6 (p = 0.003) of the FWB domain related strongly with the ECOG-PS categories. Conclusion There are indications that HRQoL questionnaire items that have to do with impairment in physical role functioning relate strongly with ECOG-PS categories.
Title: Defining the relationship between clinician-preferred ECOG performance status and patient-reported health-related quality of life scores in men with metastatic hormone-naïve prostate cancer
Description:
Abstract Background Performance status and health-related quality of life (HRQoL) are important parameters in the management of metastatic prostate cancer.
The clinician-preferred Eastern Cooperative Oncology Group performance status (ECOG-PS) may not relate with the patient-described HRQoL because the later puts into consideration some aspects of health that are not captured by the former.
The aim of this study is to define the relationship between clinician-preferred ECOG-PS and the patient-determined HRQoL in men with metastatic hormone-naïve prostate cancer (mPCa).
Methods An analytical cross-sectional study recruiting patients presenting with mPCa in Enugu, southeast Nigeria.
Two clinicians agreed on an ECOG-PS score for each study participant who in turn completed the FACT-P and the EQ-5D-5L questionnaires with interviewer-assistance where necessary.
Other medical information was retrieved from the records.
ANOVA and chi-square tests were used to compare available data across ECOG-PS preferences and ordinal logistic regression was used to determine the FACT-P questionnaire items that related significantly with the ECOG-PS preferences.
Results Of the 224 participants (mean age: 70.
62 ± 7.
34), about 60.
7% had ≥ 12years of formal education and 84.
9% had ISUP grade ≥ 3 cancer.
In all, 22.
8%, 55.
8%, 21.
0% and 0.
4% were ECOG-PS 1, ECOG-PS 2, ECOG-PS 3 and ECOG-PS 4 respectively while the mean FACT-P score, EQ-HVI and EQ-VAS score were 80.
18 ± 17.
56, 0.
524 ± 0.
324 and 60.
43 ± 9.
91% respectively.
The FACT-P score (p = 0.
002), EQ-HVI (p < 0.
001) and EQ-VAS score (p < 0.
001) varied significantly across the ECOG-PS categories.
Within the FACT-P, only questionnaire items GP3 (p = 0.
024) and GP7 (p < 0.
001) of the PWB domain, and items GF5 (p = 0.
009) and GF6 (p = 0.
003) of the FWB domain related strongly with the ECOG-PS categories.
Conclusion There are indications that HRQoL questionnaire items that have to do with impairment in physical role functioning relate strongly with ECOG-PS categories.

Related Results

Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Small Cell Lung Cancer and Tarlatamab: A Meta-Analysis of Clinical Trials
Abstract Introduction Tarlatamab is a Delta-like ligand 3 (DLL3) -directed bispecific T-cell engager recently approved for use in patients with advanced small cell lung cancer (SCL...
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract 4602: Clinicopathological and genetic features of prostate cancer in Algerian patients: First report
Abstract Background: Prostate cancer is the second most frequent malignancy (after lung cancer) in men worldwide. It is the third most common cancer in men in Algeri...
Autonomy on Trial
Autonomy on Trial
Photo by CHUTTERSNAP on Unsplash Abstract This paper critically examines how US bioethics and health law conceptualize patient autonomy, contrasting the rights-based, individualist...
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract 5758: Deletions of olfactomedin 4 gene is associated with progression of prostate cancer
Abstract The human olfactomedin 4 gene (OLFM4) encodes an olfactomedin-related glycoprotein, which our group first cloned and characterized in myeloid cells and mapp...
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Safety and Efficacy of Atezolizumab in Ovarian Cancer
Abstract Introduction Although the efficacy of PD-L1 blockade has been evaluated in analyses that combine pharmacologically distinct antibodies, the specific efficacy and safety of...
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
Grade Group 1 Prostate Cancer Outcome by Biopsy Grade and Risk Group
ImportanceAdvocates for removing the cancer label from grade group 1 (GG1) prostate cancer detected on biopsy primarily base their argument on the observation that when only GG1 is...
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract 1568: The role of CCL2 CCL17 CCL22-CCR4 axis in prostate cancer metastasis
Abstract BACKGROUND: Multiple steps and factors are involved in prostate carcinogenesis and tumor progression. The early studies have found that tumor-associated mac...

Back to Top